• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Temozolomide

Product ID T1849
Cas No. 85622-93-1
Purity ≥98%
Product Unit SizeCostQuantityStock
25 mg $111.30 In stock
100 mg $305.70 In stock
500 mg $1,157.50 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Temozolomide is a second generation imidazotetrazine anticancer chemotherapeutic that is clinically approved to treat gliobastoma multiforme, anaplastic astrocytoma, and oligodendrocytoma. Temozolomide acts as an alkylating agent, attaching alkyl groups to guanine bases in DNA and interfering with DNA replication. This compound is 100% orally bioavailable and enters the cerebrospinal fluid easily and quickly.

Product Info

Cas No.

85622-93-1

Purity

≥98%

Formula

C6H6N6O2

Formula Wt.

194.15

Chemical Name

3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5- tetrazine-8-carboxamide

IUPAC Name

3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide

Synonym

Methazolastone, Temodal, Temodar

Melting Point

212°C (dec)

Solubility

Soluble in DMSO to 39mg/mL, Water to 5 mg/mL, Ethanol <1mg/mL

Appearance

White to light pink powder

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

T1849 MSDS PDF

Info Sheet

T1849 Info Sheet PDF

Brochures

Temozolomide Flyer

References

Nagasawa DT, Chow F, Yew A, et al. Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am. 2012 Apr;23(2):307-22, ix. PMID: 22440874.

Wesolowski JR, Rajdev P, Mukherji SK. Temozolomide (Temodar). AJNR Am J Neuroradiol. 2010 Sep;31(8):1383-4. PMID: 2053882.

Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000 Jul;6(7):2585-97. PMID: 10914698.

Horing E, Harter PN, Seznec J, et al. The “go or grow” potential of gliomas is linked to the necropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress. Acta Neuropathol. 2012 Jul;124(1):83-97. PMID: 22249620.

Momiyama M, Suetsugu A, Chishima T, et al. Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice. Anticancer Res. 2013 Jan;33(1):103-106. PMID: 23267133.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only